| 3.95 Data as of May 22 |  -0.01 / -0.25%Today’s Change | 3.69 Today|||52-Week Range 7.94 | -25.33% Year-to-Date |
| Bayer's Xofigo Cleared in the US - Analyst Blog May 16 / Zacks.com | Dendreon Narrows 1Q Loss - Analyst Blog May 10 / Zacks.com |
| Previous close | 3.96 |
| Today’s open | 3.99 |
| Day’s range | 3.92 - 4.04 |
| Volume | 2,653,182 |
| Average volume (3 months) | 4,536,288 |
| Market cap | $624.1M |
| Dividend yield | -- |
| Earnings growth (last year) | -14.72% |
| Earnings growth (this year) | +40.81% |
| Earnings growth (next 5 years) | +85.00% |
| Revenue growth (last year) | -4.71% |
| P/E ratio | NM |
| Price/Sales | 2.42 |
| Price/Book | 17.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| AMAGAMAG Pharmaceuticals... | -2.68 | -10.69% |
| QDELQuidel Corp | -0.71 | -3.13% |
| ALRPRBAlere Inc | -3.80 | -1.54% |
| TRIBTrinity Biotech PLC | -0.13 | -0.77% |
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.42 |
| Annual revenue (last year) | $325.5M |
| Annual profit (last year) | -$393.6M |
| Net profit margin | -120.91% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer John H. Johnson |
Chief Financial Officer, Treasurer & Executive VP Gregory T. Schiffman, MBA, CPA |
Corporate headquarters Seattle, Washington |
.
